Browsing Tag
FAK inhibitor
1 post
Amplia Therapeutics (ASX:ATX) reports five complete responses and improved survival in ACCENT pancreatic cancer trial
Amplia Therapeutics (ASX:ATX) posts 7.8% complete response rate and 11.1-month mOS in ACCENT pancreatic cancer trial. Read the full strategic analysis.